2,701 Shares in Biogen Inc. $BIIB Acquired by Proficio Capital Partners LLC

Proficio Capital Partners LLC purchased a new stake in shares of Biogen Inc. (NASDAQ:BIIB) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 2,701 shares of the biotechnology company’s stock, valued at approximately $584,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. BlackRock Inc. bought a new stake in Biogen in the 2nd quarter valued at $3,453,878,000. LSV Asset Management increased its position in Biogen by 3.3% during the 4th quarter. LSV Asset Management now owns 316,815 shares of the biotechnology company’s stock worth $55,756,000 after buying an additional 9,976 shares during the period. Orbimed Advisors LLC bought a new position in Biogen during the 1st quarter worth $11,293,000. Catalyst Funds Management Pty Ltd acquired a new stake in shares of Biogen during the fourth quarter worth $2,006,000. Finally, Systematic Financial Management LP lifted its holdings in shares of Biogen by 256.3% during the fourth quarter. Systematic Financial Management LP now owns 16,640 shares of the biotechnology company’s stock worth $2,928,000 after buying an additional 11,970 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: China approved LEQEMBI SC-AI, Eisai and Biogen’s once-weekly subcutaneous autoinjector for patients with mild cognitive impairment or mild Alzheimer’s disease dementia. The at-home treatment provides an alternative to biweekly hospital infusions, potentially improving patient adherence, reducing clinic visits and lowering healthcare-resource requirements. China represents a substantial long-term market, with an estimated 17 million people affected by early Alzheimer’s disease in 2024. Launch is planned during Eisai’s fiscal 2026. China approval of LEQEMBI SC-AI
• Positive Sentiment: Zorevunersen data supported pipeline optimism. Four-year follow-up in Dravet syndrome showed durable seizure reductions and sustained cognitive and behavioral improvements, with a generally well-tolerated safety profile. Completion of enrollment in the Phase 3 EMPEROR study adds a meaningful late-stage development milestone for Biogen’s partnered pipeline. Zorevunersen clinical data
• Positive Sentiment: Commercial sentiment around LEQEMBI improved after Canada’s drug agency issued a positive recommendation supporting public reimbursement for eligible early-Alzheimer’s patients. Recent analyst target increases also reinforced expectations for LEQEMBI uptake and Biogen’s transition toward newer growth assets. Canada LEQEMBI reimbursement recommendation
• Neutral Sentiment: Biogen completed its acquisition of RayThera to expand into small-molecule immunology therapies. The lead program has only recently entered Phase 1, so the deal offers strategic diversification but carries clinical, execution and financial risks before it can contribute material revenue. Biogen RayThera acquisition

Biogen Stock Performance

NASDAQ BIIB opened at $222.67 on Thursday. The company has a market capitalization of $32.90 billion, a price-to-earnings ratio of 39.41, a PEG ratio of 2.39 and a beta of 0.17. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39. Biogen Inc. has a twelve month low of $135.39 and a twelve month high of $225.59. The stock has a fifty day simple moving average of $208.99 and a 200 day simple moving average of $196.25.

Biogen (NASDAQ:BIIB) last announced its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, topping analysts’ consensus estimates of $2.94 by $0.66. The business had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. Biogen’s quarterly revenue was up 3.4% on a year-over-year basis. During the same quarter last year, the firm earned $5.47 earnings per share. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Sell-side analysts expect that Biogen Inc. will post 12.39 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Needham & Company LLC upped their price target on shares of Biogen from $255.00 to $256.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Jefferies Financial Group reissued a “buy” rating on shares of Biogen in a report on Monday, July 13th. Zacks Research upgraded shares of Biogen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 28th. Morgan Stanley raised their target price on shares of Biogen from $222.00 to $231.00 and gave the stock an “equal weight” rating in a report on Thursday, July 30th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Biogen in a research note on Tuesday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $227.79.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.